Explore more press releases
Filter
Topics
Period
Filter by
recent search
Showing: 1 – 05 of 20 Press Releases
–
28 April 2025
28 April 2025
LinkedIn
Facebook
Health Canada approves IQIRVO® as a first-in-class dual-peroxisome proliferator-activated receptor treatment for primary biliary cholangitis
IQIRVO® (elafibranor) is the first new medicine approved in nearly a decade for the treatment of rare cholestatic liver disease Primary Biliary Cholangitis
–
04 May 2022
04 May 2022
Health Canada approves Ipsen’s CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory or Ineligible Differentiated Thyroid Cancer
Pivotal phase III trial data showed CABOMETYX® demonstrated a significant improvement in progression-free survival.1
–
20 October 2021
20 October 2021
Health Canada approves Ipsen’s CABOMETYX® (cabozantinib) in combination with OPDIVO® (nivolumab) as a first-line treatment for adults with advanced or metastatic renal cell carcinoma
Pivotal phase III trial data showed CABOMETYX® in combination with OPDIVO® demonstrated superior efficacy compared to sunitinib across all key endpoints, reducing the risk of death by 40 per cent,1 giving Canadians living with kidney cancer another treatment option.
–
16 March 2021
16 March 2021
Health Canada Approves INCRELEX®, First and Only Recombinant Human Insulin-like Growth Factor-1 (IGF-1) Therapy in Canada for the Treatment of Severe Growth Failure Associated with Ultra-Rare Condition in Children and Adolescents
Mississauga, ON, March 16, 2021 – Ipsen Biopharmaceuticals Canada Inc. today announced the commercial availability of INCRELEX® (mecasermin) for the treatment of growth failure in children and adolescents from 2 to 18 years with confirmed severe primary insulin-like growth factor-1 deficiency (SPIGFD),…
–
04 May 2020
04 May 2020
Ipsen enters into an option agreement with IRICoR and Université de Montréal for a discovery-stage oncology program
PARIS, France, and MONTREAL, Canada, 04 May 2020 — Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, IRICoR, a pan-Canadian research commercialization center focused on drug discovery, and Université de Montréal, today announced they entered into an option agreement…